May 21, 2020 / 10:12 AM / 4 days ago

BRIEF-Antisense Therapeutics Says Phase Ii Clinical Trial Of Atl1102 For Duchenne Muscular Dystrophy Met Primary Endpoint

May 21 (Reuters) - Antisense Therapeutics Ltd:

* PHASE II CLINICAL TRIAL OF ATL1102 FOR DUCHENNE MUSCULAR DYSTROPHY MET PRIMARY ENDPOINT

* ANTISENSE ATL1102 FINAL PHASE II DMD RESULTS EXCEED EXPECTATIONS ON SECONDARY ENDPOINTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below